Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
about
sameAs
Dietary and nutritional considerations for inflammatory bowel diseaseIntestinal microbiota in functional bowel disorders: a Rome foundation reportAntidepressants and inflammatory bowel disease: a systematic reviewA systematic review of disease-related stigmatization in patients living with inflammatory bowel diseaseOverlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?Diagnosis and management of functional symptoms in inflammatory bowel disease in remissionThe relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndromeDiagnosis of Irritable Bowel Syndrome: Role of Potential BiomarkersReview article: Description and management of fatigue in inflammatory bowel diseaseReview article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel diseaseIBS-like symptoms in patients with ulcerative colitisReview article: bile acid diarrhoea - pathogenesis, diagnosis and managementCognitive behavioral approach to understanding irritable bowel syndrome.Narcotic use and misuse in Crohn's disease.Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial."It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease.New pathophysiological mechanisms in irritable bowel syndrome.New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments.Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel diseaseAssociation of Inflammatory Bowel Disease (IBD) with Depressive Symptoms in the United States Population and Independent Predictors of Depressive Symptoms in an IBD Population: A NHANES Study.Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study.Chronic inflammation and quality of life in older adults: a cross-sectional study using biomarkers to predict emotional and relational outcomesSerotonin and GI Disorders: An Update on Clinical and Experimental Studies.Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review.Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease.Gut hormones: emerging role in immune activation and inflammation.Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation?Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis.Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders.Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders.Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls--eight years follow-up of IBS patients in primary careMicroRNA 29 targets nuclear factor-κB-repressing factor and Claudin 1 to increase intestinal permeability.Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.British Dietetic Association evidence-based guidelines for the dietary management of Crohn's disease in adults.
P2860
Q22251396-B5D7EBDB-18C5-4E5C-9BC3-72CC7A24E312Q24631357-0966687C-D308-47BD-8A6E-85FF1FF51669Q24676951-842A3955-44A7-46CE-954C-DD2BC4C85DBCQ26750421-76C7A9E8-6446-4574-BD5C-DA9EA0C147C7Q26765219-603486AF-D511-4629-806C-80257CEA32CAQ26765219-EACD843F-D539-47C2-8769-2BB429912D31Q26768264-2556A3B2-5467-482D-B5F5-6927B0CDA01DQ26783287-7332FCF5-7CD0-4CCC-9263-0679D3169324Q26783287-EF400355-A281-4F4A-9871-09D36FA6C346Q26823844-2C110E1B-893C-4EB9-B6E8-F8AA5528CD8DQ27027434-73DB2860-2317-43BF-B173-BBD604D28FBDQ28083764-E0BB9F73-525D-4591-9960-D332B04C6F9DQ28088663-6D13DE28-F7CF-4685-8E20-54D60597BEC2Q28273649-CF6B1ECA-C090-4072-A86E-AB0AAD5FAE19Q30436514-DC772336-7B78-4E3A-844F-56C0D186B838Q30459066-DAB5CC17-9BD5-45D7-BF50-79F138C1364CQ30662409-7F3C258C-185C-48F6-B798-756818D19F50Q30662409-82D64C2F-FC87-47FD-8046-F2AE5995B1CEQ33300180-059354E3-B43B-49B9-BF8B-31CA5792EE8EQ33300180-60464632-DF9D-4FD9-9096-9F6F53B8F119Q33432064-6B3D136D-E882-4987-8A2E-5F9FB22BB9B6Q33433765-D268328B-DEEF-4F43-A5EA-EEF80456D515Q33470528-7AAD1A30-D7BC-4E88-8B45-48B33DC0391AQ33578069-71F58C2A-0BD5-492F-B372-1A9AB819055DQ33578069-C783140B-CE8D-4092-B3B6-68AD96697E33Q33696448-841F7BE9-A6B4-4D18-A0E3-EA1133E8CD08Q33853184-5A12F3BF-45B1-419B-BF59-AF9997C91923Q33951233-F865DA74-85F3-408F-B10A-F3E39A25DA2FQ34094755-DCD9E417-17A2-4D40-BC69-B7905EC2E4CBQ34117832-0208B854-00E6-4052-8AC9-3E948BB02136Q34117832-2D08C121-89BC-45F0-9662-78FFD649ACA3Q34155802-465F859F-D8FB-444B-A33B-A4402BCFDA48Q34304328-C0020A95-288D-46E5-978B-F6F8E25E1395Q34304328-FC7AD951-1EC0-4020-BF4F-3D616E544C39Q34317503-7772530F-83AD-4113-A701-A82BCA4F83D2Q34317503-8DBF4EB0-BABF-4C69-89D2-ED487D960CEDQ34437200-5583264E-5D2C-4CF4-A91D-C714B8AC6803Q34457261-1DE66A87-EB54-4A49-8323-BB9E1931BADFQ34502390-17F6FD05-C311-402A-98F8-8276C8984D00Q34502390-C3F25F6B-747E-4563-BBFA-EDAAB9BC5E93
P2860
Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Quality of life in inflammator ...... ociated psychological factors.
@ast
Quality of life in inflammator ...... ociated psychological factors.
@en
Quality of life in inflammator ...... ociated psychological factors.
@nl
type
label
Quality of life in inflammator ...... ociated psychological factors.
@ast
Quality of life in inflammator ...... ociated psychological factors.
@en
Quality of life in inflammator ...... ociated psychological factors.
@nl
altLabel
Quality of life in inflammator ...... sociated psychological factors
@en
Quality of life in inflammator ...... sociated psychological factors
@nl
prefLabel
Quality of life in inflammator ...... ociated psychological factors.
@ast
Quality of life in inflammator ...... ociated psychological factors.
@en
Quality of life in inflammator ...... ociated psychological factors.
@nl
P2093
P2860
P921
P1476
Quality of life in inflammator ...... sociated psychological factors
@en
Quality of life in inflammator ...... ociated psychological factors.
@en
P2093
Einar S Björnsson
Einar S. Bjornsson
Hasse Abrahamsson
Jan Svedlund
Jenny Axelsson
Rolf Gillberg
P2860
P304
P356
10.1016/S0002-9270(01)04037-0
10.1111/J.1572-0241.2002.05475.X
P407
P577
2002-02-01T00:00:00Z